Shake-up at AstraZeneca sees drugs giant slash 700 UK jobs

Chancellor's constituency is hit as company closes R&D facility in Cheshire

AstraZeneca is cutting 700 jobs in the UK, most of them in George Osborne's Tatton constituency, as part of a global restructuring that will result in a total of about 1,600 redundancies.

In a move that angered unions and caused embarrassment for the Chancellor ahead of tomorrow's Budget, the pharmaceuticals group announced it would close its research and development operation at Alderley Park, Cheshire. About 500 jobs will be lost there over the next three years, and a further 1,600 positions will move to a new research and development centre in Cambridge. A further 150 UK jobs will be lost outside Alderley Park in the restructure, bringing total UK redundancies to more than 10 per cent of the company's existing workforce of 6,700 in Britain spread over eight sites. Some 700 non-R&D jobs will remain at Alderley Park. Another 650 jobs will go in the US.

The shake-up will prompt a $1.4bn (£930m) charge and also see AstraZeneca's headquarters move from London to Cambridge.

AstraZeneca sought to soothe its staff by announcing a £330m investment in its new R&D site in Cambridge, but unions still reacted angrily.

Unite's national officer Linda McCulloch said: "Staff will be shell-shocked by this announcement. AstraZeneca's decision to relocate over a thousand jobs to Cambridge is a massive blow for the North-west. The region desperately needs this highly skilled workforce – they make a huge contribution to the economy and to the community."

The GMB's national officer Allan Black added: "This is disastrous news for the UK, and the North-west in particular."

AstraZeneca's chief executive Pascal Soriot put a positive spin on the announcement, saying: "The changes we are proposing represent an exciting and important opportunity to put science at the heart of everything we do because our long-term success depends on improving R&D productivity and achieving scientific leadership."

Drugs that account for more than 40 per cent of AstraZeneca's sales, such as ulcer and heartburn treatment Nexium, will lose their patent protection by the end of next year. Furthermore, the patent losses will continue beyond next year, with the group's best-selling drug, Crestor, used to combat cholesterol, set to lose its US patent protection in 2016.

This will open some of AstraZeneca's biggest-selling drugs to competition from low-cost rivals and prompted the group to warn in January that its sales and profits would fall sharply this year. Mr Soriot, who took over the chief executive's reins from David Brennan last year after a series of drug-development setbacks, said at the time that internal R&D, rather than takeovers, were the key to growth.

In October, AstraZeneca suspended its share buyback programme to give it more money to invest in the business. Mr Soriot acknowledged the difficulties his restructuring plan would cause in the UK and pledged to make the process as smooth as possible.

"I recognise our plans will have a significant impact on many of our people at our sites in Cheshire and London and the surrounding communities. We are committed to treating all our employees with respect and fairness as we navigate this period of change," he said.

The restructuring will focus AstraZeneca's research in three centres: Gaithersburg, Maryland in the US, Molndal in Sweden and Cambridge.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Sales Executive / Foreign Exchange Dealer - OTE £40,000+

£16000 - £40000 per annum: Recruitment Genius: A Foreign Exchange Dealer is re...

SThree: Experienced Recruitment Consultant

£20000 - £40000 per annum + OTE + Incentives + Benefits: SThree: Established f...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE 40/45k + INCENTIVES + BENEFITS: SThree: The su...

Recruitment Genius: Collections Agent

£14000 - £16000 per annum: Recruitment Genius: This company was established in...

Day In a Page

Refugee crisis: David Cameron lowered the flag for the dead king of Saudi Arabia - will he do the same honour for little Aylan Kurdi?

Cameron lowered the flag for the dead king of Saudi Arabia...

But will he do the same honour for little Aylan Kurdi, asks Robert Fisk
Our leaders lack courage in this refugee crisis. We are shamed by our European neighbours

Our leaders lack courage in this refugee crisis. We are shamed by our European neighbours

Humanity must be at the heart of politics, says Jeremy Corbyn
Joe Biden's 'tease tour': Could the US Vice-President be testing the water for a presidential run?

Joe Biden's 'tease tour'

Could the US Vice-President be testing the water for a presidential run?
Britain's 24-hour culture: With the 'leisured society' a distant dream we're working longer and less regular hours than ever

Britain's 24-hour culture

With the 'leisured society' a distant dream we're working longer and less regular hours than ever
Diplomacy board game: Treachery is the way to win - which makes it just like the real thing

The addictive nature of Diplomacy

Bullying, betrayal, aggression – it may be just a board game, but the family that plays Diplomacy may never look at each other in the same way again
Lady Chatterley's Lover: Racy underwear for fans of DH Lawrence's equally racy tome

Fashion: Ooh, Lady Chatterley!

Take inspiration from DH Lawrence's racy tome with equally racy underwear
8 best children's clocks

Tick-tock: 8 best children's clocks

Whether you’re teaching them to tell the time or putting the finishing touches to a nursery, there’s a ticker for that
Charlie Austin: Queens Park Rangers striker says ‘If the move is not right, I’m not going’

Charlie Austin: ‘If the move is not right, I’m not going’

After hitting 18 goals in the Premier League last season, the QPR striker was the great non-deal of transfer deadline day. But he says he'd preferred another shot at promotion
Isis profits from destruction of antiquities by selling relics to dealers - and then blowing up the buildings they come from to conceal the evidence of looting

How Isis profits from destruction of antiquities

Robert Fisk on the terrorist group's manipulation of the market to increase the price of artefacts
Labour leadership: Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea

'If we lose touch we’ll end up with two decades of the Tories'

In an exclusive interview, Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea
Tunisia fears its Arab Spring could be reversed as the new regime becomes as intolerant of dissent as its predecessor

The Arab Spring reversed

Tunisian protesters fear that a new law will whitewash corrupt businessmen and officials, but they are finding that the new regime is becoming as intolerant of dissent as its predecessor
King Arthur: Legendary figure was real and lived most of his life in Strathclyde, academic claims

Academic claims King Arthur was real - and reveals where he lived

Dr Andrew Breeze says the legendary figure did exist – but was a general, not a king
Who is Oliver Bonas and how has he captured middle-class hearts?

Who is Oliver Bonas?

It's the first high-street store to pay its staff the living wage, and it saw out the recession in style
Earth has 'lost more than half its trees' since humans first started cutting them down

Axe-wielding Man fells half the world’s trees – leaving us just 422 each

However, the number of trees may be eight times higher than previously thought
60 years of Scalextric: Model cars are now stuffed with as much tech as real ones

60 years of Scalextric

Model cars are now stuffed with as much tech as real ones